At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 18 enrolled
Drug / intervention
Apixaban +1 moredrug
Likely dose
Apixaban 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Single-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Apixaban in Subjects on Hemodialysis
In Brief
A Phase 1 clinical trial evaluating Apixaban for End Stage Renal Disease. Completed, enrolled 18 participants across 1 site.
Detailed Summary
The purpose of this study is to assess the pharmacokinetics of a single oral dose of 5 mg Apixaban in subjects with normal renal function and subjects with end stage renal disease (ESRD) maintained with hemodialysis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEnd Stage Renal Disease
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedApr 2011
Enrollment StartJun 2011
Primary CompletionSep 2011
TodayJul 2026
First PostedApr 22, 2011
Enrollment StartJun 1, 2011
Primary CompletionSep 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 15.2 years ago
Interventions
Apixabandrug
Tablets, Oral, 5 mg, Once, 4 days
Apixabandrug
Tablets, Oral, 5 mg, Twice, 15 days